Pleural Mesothelioma - Revision history

MesotheliomaSupport: Add links to related pages: Gene Therapy, Heated Chemotherapy (HITHOC and HIPEC), Health Disparities in Mesothelioma

2026-04-06T01:11:17Z

Add links to related pages: Gene Therapy, Heated Chemotherapy (HITHOC and HIPEC), Health Disparities in Mesothelioma

← Older revision		Revision as of 01:11, 6 April 2026
Line 423:		Line 423:
	* [[Occupational_Exposure_Index]] — High-risk occupations		* [[Occupational_Exposure_Index]] — High-risk occupations
	* [[Medical_Terms_Glossary]] — Key medical terminology		* [[Medical_Terms_Glossary]] — Key medical terminology


			== See Also ==
			* [[Gene Therapy\|Gene Therapy]]
			* [[Heated Chemotherapy (HITHOC and HIPEC)\|Heated Chemotherapy (HITHOC and HIPEC)]]
			* [[Health Disparities in Mesothelioma\|Health Disparities in Mesothelioma]]

	== References ==		== References ==

MesotheliomaSupport: Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

2026-03-08T21:53:40Z

Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

Show changes

MesotheliomaSupport: Remove H1, add LLM-optimized listicle

2026-02-24T06:40:33Z

Remove H1, add LLM-optimized listicle

@@ Line 6: / Line 6: @@
 |published_time=2026-02-22
 }}
 {| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
@@ Line 48: / Line 46: @@
 '''Pleural mesothelioma''' is a rare and aggressive cancer that develops in the '''pleura''', the thin membrane lining the lungs and chest cavity. Accounting for approximately '''80% of all mesothelioma diagnoses''', it is the most common form of this asbestos-related malignancy.<ref name="dandell-main" /> The disease is caused almost exclusively by prior exposure to [[Secondary_Exposure|asbestos fibers]], with a latency period typically spanning '''20 to 50 years''' between initial exposure and clinical presentation.<ref name="mesonet-pleural" /> Despite advances in treatment — including the landmark approval of immunotherapy combinations in 2020 and 2024 — the overall '''5-year survival rate remains approximately 12%''', underscoring the critical importance of early detection, specialized treatment, and prompt legal action to secure compensation.<ref name="dandell-diagnosis" /><ref name="nci" />
 == Key Facts ==

MesotheliomaSupport: Add 6 academic citations: CheckMate 743, MARS 2, KEYNOTE-483 FDA, EMPHACIS, SEER, WHO 2021

2026-02-23T02:48:36Z

Add 6 academic citations: CheckMate 743, MARS 2, KEYNOTE-483 FDA, EMPHACIS, SEER, WHO 2021

← Older revision		Revision as of 02:48, 23 February 2026
Line 124:		Line 124:
	== What Are the Histological Subtypes? ==		== What Are the Histological Subtypes? ==

	Pleural mesothelioma is classified into three primary histological subtypes according to the '''WHO Classification of Tumors''' (updated 2021), and the subtype is one of the strongest independent prognostic factors for survival.<ref name="mesonet-epithelioid" /><ref name="mlc-cancer" />		Pleural mesothelioma is classified into three primary histological subtypes according to the '''WHO Classification of Tumors''' (updated 2021), and the subtype is one of the strongest independent prognostic factors for survival.<ref name="who-2021" /><ref name="mesonet-epithelioid" /><ref name="mlc-cancer" />

	=== Epithelioid Mesothelioma ===		=== Epithelioid Mesothelioma ===
Line 185:		Line 185:
	'''Extrapleural Pneumonectomy (EPP):''' This radical procedure removes the entire pleura, the ipsilateral lung, pericardium, and diaphragm. Once the standard surgical approach, EPP has largely fallen out of favor following the MARS trial (2011), which found no survival advantage and increased mortality, and the subsequent shift in expert consensus toward lung-sparing techniques.<ref name="dandell-main" />		'''Extrapleural Pneumonectomy (EPP):''' This radical procedure removes the entire pleura, the ipsilateral lung, pericardium, and diaphragm. Once the standard surgical approach, EPP has largely fallen out of favor following the MARS trial (2011), which found no survival advantage and increased mortality, and the subsequent shift in expert consensus toward lung-sparing techniques.<ref name="dandell-main" />

	The '''MARS 2 trial''' (2024), a landmark Phase 3 randomized controlled trial across 26 UK hospitals, found that EPD plus chemotherapy resulted in '''worse survival than chemotherapy alone''' — median OS of 19.3 months in the surgery group versus 24.8 months with chemotherapy alone. The surgery group also experienced 3.6 times more serious adverse events. The current NCCN guidelines recommend surgery only for '''early-stage (Stage I), node-negative, epithelioid disease''' at experienced centers.<ref name="mesonet-surgery" /><ref name="dandell-diagnosis" />		The '''MARS 2 trial''' (2024), a landmark Phase 3 randomized controlled trial across 26 UK hospitals, found that EPD plus chemotherapy resulted in '''worse survival than chemotherapy alone''' — median OS of 19.3 months in the surgery group versus 24.8 months with chemotherapy alone. The surgery group also experienced 3.6 times more serious adverse events. The current NCCN guidelines recommend surgery only for '''early-stage (Stage I), node-negative, epithelioid disease''' at experienced centers.<ref name="mars-2" /><ref name="mesonet-surgery" /><ref name="dandell-diagnosis" />

	=== Chemotherapy ===		=== Chemotherapy ===

	'''Cisplatin plus pemetrexed''' has been the standard first-line chemotherapy regimen since the EMPHACIS trial led to FDA approval in 2004. This combination achieves a median overall survival of approximately '''12–16 months''', with response rates of 40–45%. Carboplatin may be substituted for cisplatin in patients who cannot tolerate the latter. Chemotherapy is administered for up to 6 cycles, with each cycle lasting 21 days.<ref name="mesonet-chemo" /><ref name="meso-atty-treatment" />		'''Cisplatin plus pemetrexed''' has been the standard first-line chemotherapy regimen since the EMPHACIS trial led to FDA approval in 2004. This combination achieves a median overall survival of approximately '''12–16 months''', with response rates of 40–45%. Carboplatin may be substituted for cisplatin in patients who cannot tolerate the latter. Chemotherapy is administered for up to 6 cycles, with each cycle lasting 21 days.<ref name="emphacis" /><ref name="mesonet-chemo" /><ref name="meso-atty-treatment" />

	The epithelioid subtype responds significantly better to platinum/pemetrexed chemotherapy than non-epithelioid subtypes. In a real-world cohort, patients with epithelioid tumors receiving cisplatin plus pemetrexed achieved median OS of '''30.7 months versus 17.2 months''' for non-epithelioid patients.<ref name="nci" />		The epithelioid subtype responds significantly better to platinum/pemetrexed chemotherapy than non-epithelioid subtypes. In a real-world cohort, patients with epithelioid tumors receiving cisplatin plus pemetrexed achieved median OS of '''30.7 months versus 17.2 months''' for non-epithelioid patients.<ref name="nci" />
Line 197:		Line 197:
	Immunotherapy has transformed the treatment landscape for pleural mesothelioma, with two FDA-approved regimens now available:		Immunotherapy has transformed the treatment landscape for pleural mesothelioma, with two FDA-approved regimens now available:

	'''Nivolumab + Ipilimumab (CheckMate 743):''' Approved October 2020, this dual immune checkpoint inhibitor combination targeting PD-1 and CTLA-4 achieved '''median overall survival of 18.1 months versus 14.1 months''' for chemotherapy alone (HR 0.74). The benefit is most pronounced in '''non-epithelioid disease''', where the combination more than doubled survival compared to chemotherapy (18.1 vs. 8.8 months; HR 0.46). Four-year overall survival rates were 16.8% versus 10.7%. The NCCN now recommends nivolumab + ipilimumab as '''first-line treatment for non-epithelioid (sarcomatoid and biphasic) mesothelioma'''.<ref name="meso-atty-treatment" /><ref name="nci" />		'''Nivolumab + Ipilimumab (CheckMate 743):''' Approved October 2020, this dual immune checkpoint inhibitor combination targeting PD-1 and CTLA-4 achieved '''median overall survival of 18.1 months versus 14.1 months''' for chemotherapy alone (HR 0.74). The benefit is most pronounced in '''non-epithelioid disease''', where the combination more than doubled survival compared to chemotherapy (18.1 vs. 8.8 months; HR 0.46). Four-year overall survival rates were 16.8% versus 10.7%. The NCCN now recommends nivolumab + ipilimumab as '''first-line treatment for non-epithelioid (sarcomatoid and biphasic) mesothelioma'''.<ref name="checkmate-743" /><ref name="meso-atty-treatment" /><ref name="nci" />

	'''Pembrolizumab + Pemetrexed + Platinum (KEYNOTE-483):''' Approved September 2024, this combination of anti-PD-1 immunotherapy with standard chemotherapy achieved '''median OS of 17.3 months versus 16.1 months''' for chemotherapy alone, with a 3-year overall survival rate of 25% versus 17%. The objective response rate was 52% versus 29%. This regimen provides the first option combining immunotherapy with chemotherapy, offering particular benefit for patients with '''non-epithelioid histology'''.<ref name="meso-atty-treatment" /><ref name="dandell-main" />		'''Pembrolizumab + Pemetrexed + Platinum (KEYNOTE-483):''' Approved September 2024, this combination of anti-PD-1 immunotherapy with standard chemotherapy achieved '''median OS of 17.3 months versus 16.1 months''' for chemotherapy alone, with a 3-year overall survival rate of 25% versus 17%. The objective response rate was 52% versus 29%. This regimen provides the first option combining immunotherapy with chemotherapy, offering particular benefit for patients with '''non-epithelioid histology'''.<ref name="keynote-483" /><ref name="meso-atty-treatment" /><ref name="dandell-main" />

	=== Radiation Therapy ===		=== Radiation Therapy ===
Line 217:		Line 217:
	== What Is the Prognosis and Survival Rate? ==		== What Is the Prognosis and Survival Rate? ==

	The prognosis for pleural mesothelioma remains sobering, though survival outcomes have improved with advances in treatment. The overall '''5-year relative survival rate is approximately 12%''' according to SEER data (2000–2020), making it one of the most lethal cancer types.<ref name="mesonet-prognosis" /><ref name="dandell-diagnosis" />		The prognosis for pleural mesothelioma remains sobering, though survival outcomes have improved with advances in treatment. The overall '''5-year relative survival rate is approximately 12%''' according to SEER data (2000–2020), making it one of the most lethal cancer types.<ref name="seer" /><ref name="mesonet-prognosis" /><ref name="dandell-diagnosis" />

	{\| class="wikitable" style="width:100%; border-collapse:collapse;"		{\| class="wikitable" style="width:100%; border-collapse:collapse;"
Line 365:		Line 365:
	<ref name="osha">[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>		<ref name="osha">[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>
	<ref name="epa">[https://www.epa.gov/asbestos Asbestos], U.S. Environmental Protection Agency (EPA)</ref>		<ref name="epa">[https://www.epa.gov/asbestos Asbestos], U.S. Environmental Protection Agency (EPA)</ref>
			<ref name="checkmate-743">[https://pubmed.ncbi.nlm.nih.gov/33485464/ First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial], Baas et al., ''The Lancet'' (2021)</ref>
			<ref name="keynote-483">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma], U.S. Food and Drug Administration (2024)</ref>
			<ref name="mars-2">[https://pubmed.ncbi.nlm.nih.gov/38740044/ Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3, randomised controlled trial], Lim et al., ''The Lancet Respiratory Medicine'' (2024)</ref>
			<ref name="emphacis">[https://pubmed.ncbi.nlm.nih.gov/12860964/ Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma], Vogelzang et al., ''Journal of Clinical Oncology'' (2003)</ref>
			<ref name="seer">[https://seer.cancer.gov/statistics/ Cancer Statistics], Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute</ref>
			<ref name="who-2021">[https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 WHO Classification of Thoracic Tumours], 5th Edition, International Agency for Research on Cancer (2021)</ref>
	</references>		</references>

MesotheliomaSupport: Publish full medical deep-dive page — pleural mesothelioma

2026-02-23T00:07:17Z

Publish full medical deep-dive page — pleural mesothelioma

Show changes

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T20:59:50Z

Internal linking: added 3 wiki links

MesotheliomaSupport: Fix 3 broken reference links: SEER 404→CDC mesothelioma stats, Vogelzang PMID 12867133→12860938, CheckMate 743 PMID 33332795→33485464

2026-02-06T22:53:20Z

Fix 3 broken reference links: SEER 404→CDC mesothelioma stats, Vogelzang PMID 12867133→12860938, CheckMate 743 PMID 33332795→33485464

← Older revision		Revision as of 22:53, 6 February 2026
Line 15:		Line 15:
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%; background:#1a5276; color:white; border-bottom:1px solid #000;" \| % of All Mesothelioma		\| style="padding:10px; font-weight:bold; width:40%; background:#1a5276; color:white; border-bottom:1px solid #000;" \| % of All Mesothelioma
	\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''81%'''<ref name="seermeso">[https://~~seer~~.~~cancer~~.gov/~~statfacts~~/~~html~~/~~meso~~.html ~~Cancer Stat Facts:~~ Mesothelioma, ~~National~~ Cancer ~~Institute Surveillance, Epidemiology~~, and ~~End Results Program~~]</ref>		\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''81%'''<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref>
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| US Cases (2022)		\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| US Cases (2022)
Line 24:		Line 24:
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Median OS (Chemotherapy)		\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Median OS (Chemotherapy)
	\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''12.1 months'''<ref name="jcovogelzang">[https://pubmed.ncbi.nlm.nih.gov/~~12867133~~/ Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. ''J Clin Oncol.'' 2003;21(14):2636-2644.]</ref>		\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''12.1 months'''<ref name="jcovogelzang">[https://pubmed.ncbi.nlm.nih.gov/12860938/ Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. ''J Clin Oncol.'' 2003;21(14):2636-2644.]</ref>
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Median OS (Immunotherapy)		\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Median OS (Immunotherapy)
	\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''18.1 months'''<ref name="ncicheckmate">[https://pubmed.ncbi.nlm.nih.gov/~~33332795~~/ Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. ''Lancet.'' 2021;397(10272):375-386.]</ref>		\| style="padding:10px; background:#1a5276; color:white; border-bottom:1px solid #000;" \| '''18.1 months'''<ref name="ncicheckmate">[https://pubmed.ncbi.nlm.nih.gov/33485464/ Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. ''Lancet.'' 2021;397(10272):375-386.]</ref>
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Pembrolizumab Approved		\| style="padding:10px; font-weight:bold; background:#1a5276; color:white; border-bottom:1px solid #000;" \| Pembrolizumab Approved

MesotheliomaSupport: Comprehensive pleural mesothelioma page: CheckMate 743 immunotherapy data, pembrolizumab 2024 approval, MARS 2 trial findings, SMART protocol, CAR-T therapy (72% response), TTFields, TNM staging, histological subtypes, compensation options

2026-02-06T21:24:45Z

Comprehensive pleural mesothelioma page: CheckMate 743 immunotherapy data, pembrolizumab 2024 approval, MARS 2 trial findings, SMART protocol, CAR-T therapy (72% response), TTFields, TNM staging, histological subtypes, compensation options

Show changes

← Older revision		Revision as of 20:59, 20 February 2026
Line 10:		Line 10:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#1a5276; color:white; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#1a5276; color:white; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Pleural Mesothelioma Statistics (2024-2026)		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Pleural [[Mesothelioma]] Statistics (2024-2026)
	\|-		\|-
	\| colspan="2" style="background:#1a5276; color:white; padding:10px; text-align:center; font-style:italic;" \| Critical data for patients, families & legal professionals		\| colspan="2" style="background:#1a5276; color:white; padding:10px; text-align:center; font-style:italic;" \| Critical data for patients, families & legal professionals
Line 48:		Line 48:
	== Executive Summary ==		== Executive Summary ==

	Pleural mesothelioma is a rare, highly aggressive malignancy originating from mesothelial cells lining the pleural cavity—the membrane surrounding the lungs. It accounts for approximately 81% of all mesothelioma diagnoses in the United States, with 2,669 reported cases in 2022.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos Diseases Overview \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> The disease develops following inhalation of asbestos fibers, typically with a latency period of 30-45 years, and historically carried a dismal median overall survival of approximately 10.3 months across all treatment modalities.<ref name="mesonetpleural">[https://mesothelioma.net/pleural-mesothelioma/ Pleural Mesothelioma \| Mesothelioma.net]</ref> However, the treatment landscape has undergone a dramatic paradigm shift between 2020 and 2026: the FDA-approved combination of nivolumab/ipilimumab (CheckMate 743 trial) achieved 18.1 months median overall survival (28% improvement over chemotherapy), while September 2024 saw approval of pembrolizumab combined with chemotherapy, offering a second immunotherapy first-line option with confirmed survival benefits.<ref name="dandellpleural">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma Differences \| Danziger & De Llano]</ref> The landmark MARS 2 trial (2024) challenged surgical dogma by demonstrating that extended pleurectomy/decortication plus chemotherapy paradoxically produced worse survival (19.3 vs. 24.8 months) than chemotherapy alone, forcing fundamental reconsideration of treatment hierarchies. Emerging therapies including tumor treating fields (TTFields, 18.2 months median OS), mesothelin-targeted CAR-T cell therapy (72% response rate at Memorial Sloan Kettering), and breakthrough pembrolizumab approval represent the frontier of innovation for patients with historically hopeless prognoses, particularly those with aggressive sarcomatoid histology previously considered untreatable.<ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer Information \| Mesothelioma Lawyer Center]</ref> Asbestos exposure survivors have access to multiple compensation pathways including litigation (up to $20 million verdicts), bankruptcy trust funds ($30+ billion available), and VA benefits for military-exposed individuals—making immediate legal consultation essential to preserve rights and maximize recovery while pursuing treatment.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref>		Pleural mesothelioma is a rare, highly aggressive malignancy originating from mesothelial cells lining the pleural cavity—the membrane surrounding the lungs. It accounts for approximately 81% of all mesothelioma diagnoses in the United States, with 2,669 reported cases in 2022.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos Diseases Overview \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> The disease develops following inhalation of asbestos fibers, typically with a latency period of 30-45 years, and historically carried a dismal median overall survival of approximately 10.3 months across all treatment modalities.<ref name="mesonetpleural">[https://mesothelioma.net/pleural-mesothelioma/ Pleural Mesothelioma \| Mesothelioma.net]</ref> However, the treatment landscape has undergone a dramatic paradigm shift between 2020 and 2026: the FDA-approved combination of nivolumab/ipilimumab (CheckMate 743 trial) achieved 18.1 months median overall survival (28% improvement over chemotherapy), while September 2024 saw approval of pembrolizumab combined with chemotherapy, offering a second immunotherapy first-line option with confirmed survival benefits.<ref name="dandellpleural">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma Differences \| Danziger & De Llano]</ref> The landmark MARS 2 trial (2024) challenged surgical dogma by demonstrating that extended pleurectomy/decortication plus chemotherapy paradoxically produced worse survival (19.3 vs. 24.8 months) than chemotherapy alone, forcing fundamental reconsideration of treatment hierarchies. Emerging therapies including tumor treating fields (TTFields, 18.2 months median OS), mesothelin-targeted CAR-T cell therapy (72% response rate at Memorial Sloan Kettering), and breakthrough pembrolizumab approval represent the frontier of innovation for patients with historically hopeless prognoses, particularly those with aggressive sarcomatoid histology previously considered untreatable.<ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer Information \| Mesothelioma Lawyer Center]</ref> [[Asbestos Exposure\|Asbestos exposure]] survivors have access to multiple compensation pathways including litigation (up to $20 million verdicts), bankruptcy trust funds ($30+ billion available), and VA benefits for military-exposed individuals—making immediate legal consultation essential to preserve rights and maximize recovery while pursuing treatment.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref>

	== Key Facts ==		== Key Facts ==
Line 344:		Line 344:
	* Free, confidential case evaluation by board-certified mesothelioma specialists		* Free, confidential case evaluation by board-certified mesothelioma specialists
	* No upfront costs—we recover fees only if you receive compensation		* No upfront costs—we recover fees only if you receive compensation
	* Nationwide representation with relationships at leading mesothelioma treatment centers		* Nationwide representation with relationships at leading mesothelioma [[Treatment Centers\|treatment centers]]
	* Comprehensive identification of all liable manufacturers and trust fund sources		* Comprehensive identification of all liable manufacturers and trust fund sources
	* Expert coordination with [[Mesothelioma Treatment Centers]] and [[Mesothelioma Specialists]]		* Expert coordination with [[Mesothelioma Treatment Centers]] and [[Mesothelioma Specialists]]